Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Helioxanthin inhibits interleukin-1 beta-induced MIP-1 beta production by reduction of c-jun expression and binding of the c-jun/CREB1 complex to the AP-1/CRE site of the MIP-1 beta promoter in Huh7 cells
potently suppressing signaling and proliferation in cancer cells
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
It prevents palmitylation of Wnt proteins by Porcupine (a membrane-bound O-acyltransferase)
InChi: InChI=1S/C16H19ClN6O/c1-10(2)23-9-19-13-14(20-12-5-3-4-11(17)8-12)21-16(18-6-7-24)22-15(13)23/h3-5
Gefitinib - CAS# 184475-35-2 Size:Solid 2 mg Helioxanthin inhibits interleukin-1 beta-induced MIP-1Gefitinib, also known as ZD1839, is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in
US$ 125.00
US$ 75.00
US$ 125.00
US$ 65.00
US$ 96.00
US$ 89.00
US$ 55.00
US$ 125.00
US$ 89.00
US$ 55.00
US$ 125.00